Elisa Vigna

5.5k total citations · 3 hit papers
54 papers, 4.6k citations indexed

About

Elisa Vigna is a scholar working on Molecular Biology, Hepatology and Oncology. According to data from OpenAlex, Elisa Vigna has authored 54 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 30 papers in Hepatology and 17 papers in Oncology. Recurrent topics in Elisa Vigna's work include Liver physiology and pathology (30 papers), PI3K/AKT/mTOR signaling in cancer (10 papers) and Virus-based gene therapy research (8 papers). Elisa Vigna is often cited by papers focused on Liver physiology and pathology (30 papers), PI3K/AKT/mTOR signaling in cancer (10 papers) and Virus-based gene therapy research (8 papers). Elisa Vigna collaborates with scholars based in Italy, United States and Belarus. Elisa Vigna's co-authors include Luigi Naldini, Paolo M. Comoglio, George K. Michalopoulos, Giovanni Gaudino, Radha P. Narsimhan, Reza Zarnegar, Alberto Bardelli, Carola Ponzetto, Gunther Hartmann and K. Michael Weidner and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Elisa Vigna

54 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET.

1991 622 citations Luigi Naldini, Elisa Vigna et al. profile →
Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.

1991 580 citations Luigi Naldini, Elisa Vigna et al. profile →
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor.

1992 484 citations Luigi Naldini, Elisa Vigna et al. profile →

Peers

Countries citing papers authored by Elisa Vigna

Since Specialization

Citations

This map shows the geographic impact of Elisa Vigna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisa Vigna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisa Vigna more than expected).

Fields of papers citing papers by Elisa Vigna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisa Vigna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisa Vigna. The network helps show where Elisa Vigna may publish in the future.

Co-authorship network of co-authors of Elisa Vigna

This figure shows the co-authorship network connecting the top 25 collaborators of Elisa Vigna. A scholar is included among the top collaborators of Elisa Vigna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisa Vigna. Elisa Vigna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis 2024 ·Cancer Immunology Immunotherapy ·(unknown), Valeria Leuci, Annamaria Massa, (unknown), Ramona Rotolo, (unknown), (unknown), Letizia Vitali, (unknown), Valentina Tuninetti, Lorenzo D’Ambrosio, Alessandra Merlini, Elisa Vigna, Giorgio Valabrega, Luca Primo, Alberto Puliafito, Dario Sangiolo	2
2	Genetic Ablation of the MET Oncogene Defines a Crucial Role of the HGF/MET Axis in Cell-Autonomous Functions Driving Tumor Dissemination 2023 ·Cancers ·Chiara Modica, (unknown), Francesca Bersani, (unknown), Francesca Napoli, Luisella Righi, Riccardo Taulli, Cristina Basilico, Elisa Vigna	1
3	Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy 2022 ·Journal of Experimental & Clinical Cancer Research ·Cristina Chiriaco, (unknown), (unknown), Stefano Ughetto, Chiara Modica, Ilaria Martinelli, (unknown), Letizia Vitali, (unknown), Monica Casucci, (unknown), Silvia Giordano, Dario Sangiolo, Valeria Leuci, Elisa Vigna	15
4	A receptor-antibody hybrid hampering MET-driven metastatic spread 2021 ·Journal of Experimental & Clinical Cancer Research ·Chiara Modica, Cristina Basilico, Cristina Chiriaco, Nicla Borrelli, (unknown), Elisa Vigna	6
5	Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor 2021 ·Frontiers in Immunology ·(unknown), Simona Gallo, Annapia Vitacolonna, Elisa Vigna, Cristina Basilico, Francesca Montarolo, (unknown), Elena Casanova, Riccardo Miggiano, Davide M. Ferraris, Antonio Bertolotto, Paolo M. Comoglio, Tiziana Crepaldi	4
6	Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody 2016 ·Cancer Research ·Emanuela Pupo, (unknown), Barbara Lupo, Elisa Vigna, Daniele Avanzato, Timothy Perera, Livio Trusolino, Letizia Lanzetti, Paolo M. Comoglio	20
7	Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib 2016 ·Journal of Molecular and Cellular Cardiology ·Valentina Sala, Simona Gallo, Stefano Gatti, Enzo Médico, Elisa Vigna, Daniela Cantarella, (unknown), Massimo Natale, James J. Cimino, Mara Morello, Paolo M. Comoglio, Antonio Ponzetto, Tiziana Crepaldi	16
8	Inhibition of ligand‐independent constitutive activation of the Met oncogenic receptor by the engineered chemically‐modified antibody DN30 2015 ·Molecular Oncology ·Elisa Vigna, Cristina Chiriaco, (unknown), (unknown), Cristina Basilico, Fiorella Petronzelli, Paolo M. Comoglio	17
9	Targeting the oncogenic Met receptor by antibodies and gene therapy 2014 ·Oncogene ·Elisa Vigna, Paolo M. Comoglio	30
10	Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET 2013 ·Clinical Cancer Research ·Cristina Basilico, Selma Pennacchietti, Elisa Vigna, Cristina Chiriaco, Sabrina Arena, Alberto Bardelli, Donatella Valdembri, Guido Serini, Paolo Michieli	138
11	A Highly Potent and Specific MET Therapeutic Protein Antagonist with Both Ligand-Dependent and Ligand-Independent Activity 2013 ·Molecular Cancer Therapeutics ·Shane A. Olwill, (unknown), Hendrik Gille, Elisa Vigna, Gabriele Matschiner, (unknown), Bradley M. Lunde, Jakub Jaworski, James F. Burrows, Cristina Chiriaco, Hans Christian, Martin Hülsmeyer, Stefan Trentmann, (unknown), Andreas M. Hohlbaum, Laurent Audoly	25
12	Human cord blood CD34⁺ progenitor cells acquire functional cardiac properties through a cell fusion process 2011 ·American Journal of Physiology-Heart and Circulatory Physiology ·Daniele Avitabile, (unknown), Chiara Brioschi, Valeria Parente, Gabriele Toietta, Paolo Devanna, Mirko Baruscotti, Silvia Truffa, Angela Scavone, Francesca Rusconi, Andrea Biondi, Yuri D’Alessandra, Elisa Vigna, Dario DiFrancesco, Maurizio Pesce, Maurizio C. Capogrossi, Andrea Barbuti	26
13	The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation 2009 ·Journal of Clinical Investigation ·Riccardo Taulli, Francesca Bersani, Valentina Foglizzo, Alessandra Linari, Elisa Vigna, Marc Ladanyi, Thomas Tuschl, Carola Ponzetto	226
14	“Active” Cancer Immunotherapy by Anti-Met Antibody Gene Transfer 2008 ·Cancer Research ·Elisa Vigna, Giovanni Pacchiana, Massimiliano Mazzone, Cristina Chiriaco, (unknown), Cristina Basilico, Selma Pennacchietti, Paolo M. Comoglio	32
15	Functional properties of cells obtained from human cord blood CD34⁺ stem cells and mouse cardiac myocytes in coculture 2008 ·American Journal of Physiology-Heart and Circulatory Physiology ·Alessia Orlandi, (unknown), Daniele Avitabile, Giuseppina Bonanno, Giovanni Scambia, Elisa Vigna, Francesca Grassi, Fabrizio Eusebi, Sergio Fucile, Maurizio Pesce, Maurizio C. Capogrossi	10
16	MET Overexpression Turns Human Primary Osteoblasts into Osteosarcomas 2006 ·Cancer Research ·Salvatore Patanè, Sofia Avnet, Nadia Coltella, Barbara Costa, (unknown), Martina Olivero, Elisa Vigna, Luigi Naldini, Nicola Baldini, Riccardo Ferracini, Simona Corso, Silvia Giordano, Paolo M. Comoglio, Maria Flavia Di Renzo	104
17	Efficient Tet-Dependent Expression of Human Factor IX in Vivo by a New Self-Regulating Lentiviral Vector 2005 ·Molecular Therapy ·Elisa Vigna, Mario Amendola, Fabrizio Benedicenti, Andrew D. Simmons, Antonia Follenzi, Luigi Naldini	54
18	Hepatocyte Growth Factor Is a Regulator of Monocyte-Macrophage Function 2001 ·The Journal of Immunology ·Francesco Galimi, Erika Cottone, Elisa Vigna, N. Arena, Carla Boccaccio, Silvia Giordano, Luigi Naldini, Paolo M. Comoglio	108
19	Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET 1999 ·Oncogene ·Elisa Vigna, Daniela Gramaglia, Paola Longati, Alberto Bardelli, Paolo M. Comoglio	56
20	The Tyrosine Kinase Encoded by the MET Proto-Oncogene Is Activated by Autophosphorylation 1991 ·Molecular and Cellular Biology ·Luigi Naldini, Elisa Vigna, Riccardo Ferracini, Paola Longati, Lucia Gandino, María Prat, Paolo M. Comoglio	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact